ClearPoint Neuro (CLPT) Earnings Date & Reports

Key Takeaways

• Total revenue reached $12.08 million in the third quarter of 2026, up 36% from $8.86 million a year earlier.
• Product revenue climbed 47% to $7.89 million, while service and other revenue rose 20% to $4.18 million.
• Net loss per share of $0.24 was narrower than the consensus estimate of roughly $0.27, even as the absolute net loss widened to $7.46 million.
• Revenue of $12.08 million came in modestly below the approximately $12.30 million analyst consensus, a slight shortfall driven by segment mix.
• Cash and cash equivalents stood at about $46.2 million at quarter-end, supporting the company's ongoing integration and growth investments.
• For more context on CLPT, review its Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Explore Trending AI Robots to see AI-driven trading strategies in action.

Earnings Context and Why It Matters

ClearPoint Neuro is a commercial-stage medical device company that provides precise navigation to the brain and spine, along with preclinical services for controlled drug and device delivery. Its quarterly results matter to investors because the company is balancing rapid top-line growth with heavy investment in its expanded neurosurgery portfolio, including the IRRAflow catheter acquired through the IRRAS transaction. The third quarter offers a fresh read on whether biologics and drug delivery partnerships, capital equipment placements, and the newer neurocritical care business can collectively sustain momentum while the company remains unprofitable. Given a history of missing consensus estimates in recent quarters, this report also tests whether execution is improving against Wall Street's expectations.

Reported Results

For the three months ended September 30, 2026, ClearPoint Neuro reported total revenue of $12.08 million, an increase of 36% compared with $8.86 million in the same period of 2025. Product revenue rose to $7.89 million from $5.36 million, while service and other revenue increased to $4.18 million from $3.50 million.

Gross profit grew to $7.06 million from $5.60 million, reflecting a gross margin of approximately 58%. Operating expenses rose across the board, with sales and marketing expenses climbing to $5.53 million from $3.84 million and research and development (R&D) costs increasing to $4.02 million from $3.45 million. The operating loss widened to $6.33 million from $5.28 million, and the net loss was $7.46 million, or $0.24 per share, compared with a net loss of $5.89 million, or $0.21 per share, a year earlier.

Measured against expectations, the reported per-share loss of $0.24 was narrower than the consensus estimate of roughly $0.27, while revenue of $12.08 million fell slightly short of the approximately $12.30 million consensus. For the first nine months of 2026, revenue totaled $35.08 million, up from $26.56 million, with a net loss per share of $0.94.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like CLPT, the AI Screener can help identify comparable setups and monitor shifting market conditions in one place.

Market Reaction and Investor Sentiment

Heading into the report, sentiment around ClearPoint Neuro was cautious. The company had missed consensus earnings per share (EPS) in each of its prior eight quarters, and its shares had traded well below their 52-week high, reflecting concerns about widening losses and the cost of integrating the IRRAS business. The third-quarter results were mixed: the narrower-than-expected per-share loss provided a measure of relief, but the slight revenue shortfall kept expectations in check.

Investors are likely to focus on whether the company's double-digit revenue growth can be sustained without further acceleration in operating losses. Rising sales and marketing spending remains a key area of scrutiny, as it pressures profitability even while the top line expands. The stock's post-earnings trading will hinge on management's commentary regarding integration progress, cash burn, and the trajectory of the biologics and drug delivery segment.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should monitor several drivers behind ClearPoint Neuro's growth story. The first is execution of the IRRAS integration, particularly the adoption of the IRRAflow catheter in neurocritical care and the build-out of the expanded commercial team. Successful integration is central to management's plan to broaden revenue beyond its core navigation franchise.

The biologics and drug delivery business remains another important variable. Revenue from this segment depends heavily on the clinical trial activity and regulatory progress of pharmaceutical partners, which can shift from quarter to quarter and introduce volatility into the company's results.

Cost management will also be a focal point. With sales and marketing and R&D expenses rising faster than revenue, investors will watch whether gross margin gains and operating leverage eventually narrow the company's losses. Cash burn and the roughly $46 million cash balance provide runway, but continued investment means the path to profitability remains a multi-year narrative.

Finally, any updates to full-year 2026 guidance and forward commentary on capital equipment placements will shape expectations. As with any early-stage medical technology company, regulatory developments, reimbursement trends, and partner clinical outcomes can materially influence the trajectory of the business.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations